ERBB3 and non-small cell lung carcinoma: Similar observations were made with HER3 knockdown and brigatinib treatment, suggesting that upregulation of the HER3 signaling pathway may promote the survival of a subset of ALK-rearranged NSCLC cells with mesenchymal features when ALK signaling is inhibited by alectinib exposure for 72 h (Fig. 4c).